<h4>Purpose</h4>To evaluate the impact of BCR-ABL1 transcript type on outcome in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs).<h4>Methods</h4>PubMed, Embase and Cochrane library were systematically searched for relevant studies. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.